Hold AMGN with staged scaling plan anchored to 10 EMA at $409.90; do not add at $419
Hold existing AMGN core position with $398 close-based trailing stop for current holders; do NOT initiate new exposure at $419. Pre-commit four-tranche staged scaling plan anchored to technical events with 10 EMA at $409.90 as most likely first add zone. Architectural fix: any new tranche entered near $395-410 must have protective stop below fill at $383-388, not at $398. Thesis-level hard exit on daily close below 50 SMA at $371.70. No increase until MACD histogram rebuilds positive expansion or price confirms $432.88 breakout on >3M shares.
| Position | Action |
|---|---|
| Current weight | Hold existing position at current weight |
| MACD histogram rebuilds positive expansion or price confirms $432.88 breakout on >3M shares | May consider staged additions |
| Any new tranche entered near $395-410 | Protective stop BELOW fill at $383-388 (not $398) |
AMGN at $419 is not a late-stage exhausted rally but an early-stage fundamental re-rating driven by the company's first $10B revenue quarter, 66% net income growth, and a 50% forward EPS expansion that leaves a 37% DCF discount vs. current price.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | $409.90 | neutral |
| close_50_sma | $371.70 | bullish |
| close_200_sma | $347.25 | bullish |
| rsi | 71.91 | bearish |
| bollinger_middle | $395.11 | bullish |
| bollinger_upper_band | $432.88 | neutral |
| macd | 14.45 | bullish |
| macd_signal | 12.93 | bullish |
| macd_histogram | 1.52 | bearish |
| atr | 10.60 | neutral |
| vwma | $401.30 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price confirms $432.88 breakout on >3M shares
Then: Stage 2+ additions
The stock trades at 17.3x forward earnings on a $24.28 consensus, implying ~50% one-year EPS growth with operating margins at 35.5%, compressing PEG organically as forward EPS catches up.
↩ rebuts: “Bear 'PEG of 2.18 is stretched' argument”
· concedes: Bear structural caution on multiple product dependencies is acknowledged; New entrants should scale in on any weakness below $410 rather than chase at current levels; Existing holders should use a $398 trailing stop for risk management; Bear is correct that RSI at 71.91 is elevated and warrants monitoring, though not extreme (danger zone is 80+)
AMGN at $419 is a structurally overvalued entry point where the stock has already priced in an aggressive consensus that requires near-perfect execution across MariTide, pipeline, and macro conditions simultaneously.
· concedes: The deleveraging trajectory is real and debt is declining nominally over time; The long-term business fundamentals of Amgen are constructive; MariTide does represent a legitimate obesity pipeline asset with differentiation potential (CVOT focus); The core business has proven resilient and the portfolio of 22 products provides diversification; Existing holders should hold core positions with discipline
→ vs conservative: Conservative treats timing indicators (RSI 71.91, MACD histogram 52% decline, Bollinger %B 0.82) as valuation metrics; RSI above 70 is not automatic sell signal and MACD remains decisively positive with no histogram cross below zero
→ vs conservative: Waiting for 50-day SMA near $371.70 requires AMGN to surrender >11% of current value even though 10-day, 50-day, and 200-day trends remain bullishly aligned
→ vs conservative: Debt of ~$57.3B is manageable given declining net debt ($48.13B to $43.32B), ~$14B cash, ~$17.3B EBITDA, and 6.4x interest coverage
→ vs conservative: Obesity drug exposure not required for thesis; MariTide and pipeline provide optionality while current 22-product portfolio with 17 >$1B products provides breadth
→ vs neutral: Neutral 'balanced' stance incorrectly assigns equal weight to early-stage fundamental transformation and ordinary indicator cooling; evidence is materially skewed bullish
→ vs neutral: Muted market reaction to raised guidance confirms lack of retail euphoria (social sentiment only 6.3/10, no meaningful Reddit posts) rather than poor execution; absence of crowding is healthy
→ vs conservative: Entry at $395 and stop loss at $398 cannot both apply to new position; $398 is valid trailing stop for existing position but new purchases need stop below fill at $383-$384
→ vs conservative: Waiting for RSI below 65 AND rebuilt MACD histogram is too restrictive; breakout can occur with elevated RSI and waiting for complete momentum reset may cause stock to run away
| bullish |
Support: 409.9 · 395.11 · 371.7 · 347.25 | Resistance: 432.88 · 425 · 420
AMGN exhibits a strong structural uptrend with all major moving averages and volume indicators confirming bullish alignment. However, the rally has reached late-stage extension: RSI is approaching overbought territory at 71.91, the MACD histogram has declined 52% from its peak, and price sits at 82% of the Bollinger Band range. Resistance is encountered at the Bollinger Upper Band ($432.88) and recent intraday highs ($420-425). Existing holders should maintain positions with trailing stops at $398 (2x ATR below 10 EMA), while new entries should wait for pullbacks to $395-$410 for improved risk/reward. A close below the 50 SMA ($371.70) would break the medium-term trend and warrant full exit.
Market Cap
$226.88 B
Current Price
~$419.50
52-Week High
$421.79
52-Week Low
$269.77
50-Day MA
$370.22
200-Day MA
$349.39
Beta
0.413
Dividend Yield
2.43%
P/E (TTM)
26.03
Forward P/E
17.27
PEG
2.18
P/B
19.40
EPS (TTM)
$16.11
Forward EPS
$24.28
Revenue (TTM)
$38.10 B
Gross Profit (TTM)
$27.39 B
Gross Margin
~71.9%
EBITDA (TTM)
$17.27 B
Operating Margin
35.5%
Profit Margin
22.95%
Return on Equity
91.5%
Return on Assets
8.67%
FCF (TTM)
$8.65 B
FCF Margin
22.7%
FY2021 Revenue
$26.32 B
FY2022 Revenue
$26.32 B
FY2023 Revenue
$28.19 B
FY2024 Revenue
$33.42 B
FY2025 Revenue
$36.75 B
FY2024 Net Income
$4.09 B
FY2025 Net Income
$7.71 B
FY2025 Diluted EPS
$14.23
Q2 2026 Revenue
$10.05 B
Q2 2026 Operating Income
$3.51 B
Q2 2026 Net Income
$2.38 B
Q2 2026 Diluted EPS
$4.37
Q2 2026 COGS
$2.81 B
Q2 2026 R&D
$1.87 B
Q2 2026 SG&A
$1.75 B
Q2 2026 Tax Rate
~14.2%
Total Assets (6/30/2026)
$95.64 B
Total Liabilities (6/30/2026)
$83.95 B
Stockholders' Equity (6/30/2026)
$11.69 B
Tangible Book Value (6/30/2026)
-$27.47 B
Goodwill + Intangibles (6/30/2026)
$39.16 B
Cash & ST Investments (6/30/2026)
$13.99 B
Total Debt (6/30/2026)
$57.30 B
Net Debt (6/30/2026)
$43.32 B
Working Capital (6/30/2026)
$9.46 B
Current Ratio (6/30/2026)
1.37
D/E Ratio (6/30/2026)
490%
Interest Coverage
~6.4x
Annual Dividend (2025)
$5.12 B
Annual Dividend Growth
$4.20B → $4.56B → $4.83B → $5.12B
Annual CapEx (2025)
$1.86 B
FY2025 FCF
$8.10 B
FY2024 FCF
$10.39 B
Strengths
Concerns
Amgen is a high-quality, defensive late-stage growth biotech compounder with strong fundamentals anchored by 71.9% gross margins and 35.5% operating margins. The Q2 2026 breakout — first $10 B revenue quarter with 66% EPS growth — signals a potential inflection as the GLP-1 obesity franchise (MariTide) ramps. The stock trades near its 52-week high ($421.79) with a reasonable 17.3x forward P/E given ~50% EPS growth expectations, though a 2.18 PEG and 19.4x P/B mean growth is already priced in. The $57.3 B debt load remains the primary structural concern, but net debt is declining and FCF of $8.65 B comfortably covers the $5.5 B dividend, while the 0.41 beta offers defensive characteristics. Pipeline execution (especially MariTide launch and CVOT data) is the critical variable for upside, with receivables monitoring warranted given the 41% YoY spike.
Macro: Higher-for-longer Fed regime (85% no-cut consensus per Polymarket, $7.3M traded); 30-year Treasury at 19-year high; low US recession odds (8%); defensive rotation into non-tech innovation plays explicitly named by Cramer; oil/geopolitical risk elevated (Trump threats re: Oman, Libya pipeline); pharma named as a sector rotation beneficiary alongside JNJ and LLY.